AUSTIN, Texas , Sept. 11, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Monday, September 14 th at 8:30 a.m.
AUSTIN, Texas , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present a corporate overview at H.C. Wainwright’s 22 nd Annual Global Investment Conference .
Patent Protection Runs Through Year 2037, Plus Extensions AUSTIN, Texas , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it was granted U.S. Patent No. 10,760,052 on September 1, 2020 .
- Sumifilam Is First of a New Class of Drugs That Target Filamin Proteins - - A Commercial Brand Name for Sumifilam is Expected at a Future Date - AUSTIN, Texas , Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s
- Final Clinical Results of a Phase 2b Study i n Alzheimer’s Disease with Lead Drug Candidate, PTI-125, Expected to be Announced September 2020 - - SavaDx Demonstrates Direct Evidence of Target Engagement & Treatment Effects - - Open-label Study Of PTI-125 Reaches >50% Enrollment - AUSTIN, Texas ,
AUSTIN, Texas , July 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that its lead neuroscientist, Lindsay H. Burns , PhD, will give a keynote presentation at the Biomarkers for Alzheimer’s Disease Summit , a
AUSTIN, Texas , June 16, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that the Company will be added to the Russell 2000 ® and Russell 3000 ® Indexes, effective after the close of the U.S.
- High Variability in Levels of Biomarkers in Control Arm of Phase 2b Study May Drive Reassessment of Overall Study Results - - Effects Of PTI-125 on Cognition, Other Analysis and Data Expected 2 nd Half 2020 - - Updated Corporate Presentation Now Available on Website - AUSTIN, Texas , June 03,
- Study Showed High Variability in Levels of CSF Biomarkers Over 28 Days - - Drug Was Safe and Well-tolerated - AUSTIN, Texas , May 15, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reported top-line results from a Phase 2b study of PTI-125, its lead investigational drug, in
